• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Resubmission Confirmation Letter - Anascorp

 

Our STN: BL 125335/0
 
Rare Disease Therapeutics, Inc.
Attention: Mr. Milton H Ellis
2550 Meridian Boulevard, Suite 150
Franklin, TN 37067
 
Dear Mr. Ellis:
 
We have received your January 31, 2011 resubmission to your biologics license application for Centruroides (Scorpion) Immune F(ab)2 Intravenous (Equine) on February 1, 2011.
 
The resubmission contains your responses to our July 23, 2009 complete response letter. 
 
We consider this a complete, Class 2 response to our action letter. Therefore, the user fee goal date is August 3, 2011.
 
If you have any questions, please contact the Regulatory Project Manager, Debra Cordaro, at 301-827-6157.
 
Sincerely yours,
 
 
 
Alan E. Williams, Ph.D.
Associate Director for Regulatory Affairs
Acting Chief, Regulatory Project
 Management Branch
Office of Blood Research and Review
Center for Biologics